证券代码：002250 证券简称：联化科技 公告编号：2023-034 联化科技股份有限公司 第八届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）第八届董事会第八次会议通知 于2023年8月14日以电子邮件方式发出。会议于2023年8月24日在联化科技会议室 以通讯表决的方式召开。会议应出席董事7人，实际出席董事7人。公司监事、高 级管理人员列席了本次会议，会议由董事长王萍女士召集和主持，符合《公司法》、 《证券法》等法律法规、部门规章、规范性文件及《公司章程》的有关规定。会 议形成如下决议： 一、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过《2023年 半年度报告及其摘要》。 公司原董事George Lane Poe先生已辞去董事及董事会专门委员会委员职务， 公司于2023年7月24日召开第八届董事会第七次会议审议通过了《关于补选第八 届董事会董事的议案》，并于2023年8月10日召开2023年第一次临时股东大会审议 通过了上述议案，补选樊小彬先生为公司第八届董事会董事，任期自股 ...

证券代码：002250 证券简称：联化科技 公告编号：2023-033 联化科技股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 1、本次股东大会无否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间：2023年8月10日（星期四）15时 2、会议地点：浙江省台州市黄岩区劳动北路118号总商会大厦17楼会议室 3、会议召集人：联化科技股份有限公司董事会 4、会议方式：现场投票与网络投票相结合的方式 5、现场会议主持人：董事长王萍女士 6、会议的召集、召开与表决程序符合《公司法》、《上市公司股东大会规则》、 《深圳证券交易所股票上市规则》及《公司章程》等法律、法规及规范性文件的规 定。 特别提示： （二）会议出席情况 出席现场会议的股东及股东授权代表共2名，代表有表决权的股份数4,638,770 股，占公司股份总数的0.5024%；参加网络投票的股东共11名，代表有表决权的股 份数245,038,167股，占公司股份总数的26.5409 ...

北京市嘉源律师事务所 关于联化科技股份有限公司 2023年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 北京BEIJING·上海SHANGHAI·深圳SHENZHEN·香港HONG KONG·广州GUANGZHOU·西安XI'AN 致：联化科技股份有限公司 北京市嘉源律师事务所 关于联化科技股份有限公司 2023年第一次临时股东大会的 法律意见书 嘉源（2023）-04-613 北京市嘉源律师事务所（以下简称"本所"）接受联化科技股份有限公司（ 以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司 股东大会规则》（以下简称"《股东大会规则》"）等现行有效的法律、行政法 规、部门规章、规范性文件（以下简称"法律法规"）以及《联化科技股份有限 公司章程》（以下简称"《公司章程》"）的有关规定，指派本所律师对公司2023 年第一次临时股东大会（以下简称"本次股东大会"）进行见证，并依法出具本 法律意见书。 为出具本法律意见书，本所指派律师现场见证了本次股东大会，查阅了公司 提供的 ...

联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20230724 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □其他 中邮证券 张泽亮、李欣然 招商基金 于凡真 参与单位名称及人员 广发证券 李凌芳 中融基金 张智浩 姓名 南土资产 许智涵 太平基金 夏文奇 弘尚资产 沙正江 时间 2023 年 7 月 24 日 地点 公司上海办 上市公司接待人员姓 高级副总裁、董秘 陈飞彪 名 证券事务代表 戴依依 1、公司上半年业绩情况如何？ 公司上半年业绩较去年同期有所下滑，原因主要是公司植 保客户进入"去库存"行情，作为其定制服务解决方案提供商， 公司植保事业部收入出现一定程度下降，进而导致公司净利润 下降。公司将继续积极做好生产、研发和管理等工作，提高研 发硬实力，优化产能，拓展市场，推动公司快速发展。 2、公司医药业务发展情况如何？ 投资者关系活动主要 公司医药业务较去年相比，保持稳步发展的趋势。公司医 内容介绍 药验证项目正在按计划稳步推进，目前已有部分项目完成验 证，并逐步放量生产。在完成已有验证 ...

Group 1: Company Performance and Challenges - The main reason for the loss of the UK subsidiary in 2022 was the upgrade of production lines, which led to a decrease in capacity utilization and consequently reduced revenue. Additionally, rising energy prices and exchange losses due to international situation changes contributed to the losses. As of now, the upgrade work has been largely completed [1]. - The company began operating in business divisions in 2015, establishing the functional chemicals division to leverage its accumulated technology and experience. This division has defined a strategy for entering the new energy market based on industry development and market conditions [1]. Group 2: New Energy Sector Development - The company believes that the rapid development of the new energy industry, with its long market cycles and high importance, aligns with its mission of "green chemistry and technology creating a better life." This alignment is consistent with the company's values and capabilities [1]. - Currently, the company is confident in developing more products in the new energy and new materials sectors, accelerating the execution of its new energy strategy and project implementation [1]. Group 3: Product Development and Market Conditions - The lithium hexafluorophosphate product is currently in the trial production stage, with plans to continue improving quality systems and production processes. The development of lithium difluoro(oxalato)borate and other products is proceeding as scheduled [2]. - The global plant protection market has shifted from a "stockpiling" phase to a "de-stocking" phase due to geopolitical tensions, which is a normal market reaction. The company continues to enhance communication with customers and improve technology to mitigate negative impacts from market fluctuations [2]. Group 4: CRO Business Development - The company has established a CRO platform and team to better meet new customer demands, providing one-stop solutions. The CRO platform has officially commenced operations [2].

联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20230518 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □其他 长城证券 肖亚平 中金公司 裘孝峰、李熹凌 浙江正植 项敬康 弘尚资产 沙正江 中银国际 范琦岩 诺安基金 张伟民 参与单位名称及人员 价值在线 黄新考 湘财证券 孙皓、朱春兰 姓名 山西证券 程俊杰 个人投资者 侯传波 个人投资者 张付云 个人投资者 李永华 个人投资者 冯大彬 时间 2023 年 5 月 18 日 地点 黄岩耀达酒店会议室 董事长、总裁 王萍 副董事长 彭寅生 董事 George Poe 董事、高级副总裁 何春 上市公司接待人员姓 独立董事 Zhang Yun 高级副总裁 樊小彬 名 高级副总裁、董秘 陈飞彪 财务总监 薛云轩 公司医药事业部负责人 张建中 2022 年度实现营业收入为 786,546.56 万元，比上年同期增 加 19.41%，其中主营业务收入中的工业业务收入为 785,629.59 万元，比上年同期增加 21.31%；利润总额为 94,443 ...

6、CRO 业务前景如何？目前市场对此业务较担忧。 跨国药企对合作伙伴提出了"一体化、端到端"的要求。 近 10 年来，针对前期药物开发阶段的服务（CRO 业务）呈现了 飞速发展的状态，国内工程师红利推动了中国制造业整体转型 升级，国内人口受教育程度的提高也为 CRO 业务的发展提供了 非常优质的环境。随着我们 CRO 团队建立，将加深与客户关系 黏性，从提供技术解决方案、合成制造逐渐提供覆盖从研发到 商业化生产的全产业链的 CXO 服务。 7、请问（1）、公司去年及今年的新增产能与未来市场需求是否 契合？是否存在新增产能不符合未来几年的市场需求？（2） 近期是否有新增大订单，或者与潜在大客户开展销售的商务谈 判？ 联化科技股份有限公司投资者关系活动记录表 | 证券代码：002250 | 证券简称：联化科技 编号：20230428 | | --- | --- | | 投资者关系活动类别 □特定对象调研 | □分析师会议 | | | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称及人员 | 参与公司 2022 年度业绩说明会的投资者 | | ...

Financial Performance - Revenue for Q1 2023 reached ¥1,957,286,746.09, an increase of 15.61% compared to ¥1,693,054,812.68 in the same period last year[4] - Net profit attributable to shareholders decreased by 39.85% to ¥44,586,378.55 from ¥74,122,394.99 year-on-year[4] - Operating profit decreased to CNY 89,342,413.99, a decline of 29% from CNY 125,781,271.03 in Q1 2022[17] - The company reported a total comprehensive income of CNY 61,039,819.41, compared to CNY 76,597,566.88 in the same quarter last year[18] - Earnings per share (EPS) for Q1 2023 was CNY 0.05, down from CNY 0.08 in Q1 2022[18] Cash Flow - Net cash flow from operating activities fell by 50.01% to ¥232,773,328.32, down from ¥465,654,770.34 in the previous year[4] - Cash flow from operating activities was CNY 1,879,602,203.12, down 19.7% from CNY 2,339,136,126.31 in Q1 2022[20] - Total cash inflow from operating activities was ¥2,346,423,674.88, while cash outflow was ¥2,113,650,346.56, resulting in a net increase of ¥232,773,328.32[21] - The company reported a total cash outflow for operating activities of ¥2,113,650,346.56, which is an increase from ¥2,055,853,904.00 in Q1 2022[21] - The ending balance of cash and cash equivalents was ¥567,822,192.58, compared to ¥733,861,728.76 at the end of Q1 2022[21] Assets and Liabilities - Total assets decreased by 2.15% to ¥14,686,639,932.71 from ¥15,008,660,120.73 at the end of the previous year[4] - Total current assets amount to ¥6,022,050,762.92, a decrease from ¥6,388,619,191.46 at the beginning of the year[15] - Total liabilities amounted to CNY 7,339,409,343.81, a decrease of 5.8% from CNY 7,790,727,890.92 at the end of the previous period[17] - Long-term borrowings increased by 37.65% to ¥2,086,153,500.00, indicating additional financing activities[9] - Short-term borrowings decreased to ¥1,273,892,681.12 from ¥1,702,001,075.05[15] Research and Development - Research and development expenses increased by 41.60% to ¥103,353,730.08, reflecting higher investment in R&D[9] - Research and development expenses increased to CNY 103,353,730.08, up 41.4% from CNY 72,988,361.85 in the previous year[17] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 20,557[11] - The largest shareholder, Mu Jinxiang, holds 25.40% of shares, totaling 234,535,853 shares[11] Other Income and Expenses - The company received government subsidies amounting to ¥4,011,991.93 during the quarter[6] - Other comprehensive income rose by 72.81% to ¥8,233,266.17, primarily due to foreign currency translation differences[9] - The company received tax refunds amounting to CNY 141,487,812.54 during the quarter, compared to CNY 158,296,714.21 in Q1 2022[20] - The company received ¥19,768,051.85 from other investment activities, a significant decrease from ¥98,074,349.16 in the previous year[21] - The company paid ¥783,038,860.00 in debt repayments during the quarter, compared to ¥610,598,620.00 in Q1 2022[21]

Financial Performance - The company's operating revenue for 2022 was CNY 7,865,465,550.37, representing a 19.41% increase compared to CNY 6,586,780,685.31 in 2021[21]. - The net profit attributable to shareholders for 2022 was CNY 696,838,439.53, a significant increase of 120.93% from CNY 315,405,020.68 in 2021[21]. - The net profit after deducting non-recurring gains and losses was CNY 507,731,875.98, up 76.21% from CNY 288,143,739.71 in 2021[21]. - The basic earnings per share for 2022 was CNY 0.75, a 120.59% increase compared to CNY 0.34 in 2021[21]. - The total assets at the end of 2022 were CNY 15,008,660,120.73, an 18.72% increase from CNY 12,641,780,515.38 at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were CNY 6,951,263,314.13, a 10.32% increase from CNY 6,301,198,272.75 at the end of 2021[21]. - The company reported a net cash flow from operating activities of CNY 638,760,811.35, a decrease of 13.42% from CNY 737,788,383.17 in 2021[21]. - The total profit for 2022 was 94,443.92 million CNY, reflecting a significant increase of 126.57% compared to the previous year, while net profit attributable to shareholders reached 69,683.84 million CNY, up by 120.93%[69]. - The total operating revenue for 2022 reached ¥7,865,465,550.37, representing a year-on-year increase of 19.41% compared to ¥6,586,780,685.31 in 2021[93]. - The main business revenue accounted for ¥7,856,295,870.66, which is 99.88% of total revenue, with a year-on-year growth of 19.85%[93]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, with no bonus shares issued[5]. - The total distributable profit for shareholders was 2,266,488,377.88 CNY, with cash dividends accounting for 100% of the profit distribution[177]. - The cash dividend distribution plan requires approval from the annual general meeting and must be implemented by the board within two months[178]. Research and Development - The company emphasizes its focus on research and development of new products and technologies to enhance market competitiveness[12]. - The company is actively involved in the development and collaboration of innovative drugs, with a focus on clinical phase II and III pipeline products[37]. - The company has established a new R&D service base in 2022, increasing its investment in research and development, particularly in areas like PROTAC and Linker technologies[56]. - R&D investment increased by 24.47% to ¥394,713,816.88 in 2022, representing 5.02% of total revenue[108]. - The number of R&D personnel rose by 7.02% to 777, with a notable increase in master's degree holders by 17.69% to 153[108]. Market and Industry Trends - The global agricultural market size in 2022 was estimated to reach USD 78 billion, with a growth rate of over 5%[30]. - The global pharmaceutical R&D investment is projected to grow from $243.7 billion in 2022 to $328.8 billion by 2026, with a compound annual growth rate (CAGR) of approximately 7.8%[32]. - The global CDMO market size increased from $39.4 billion in 2017 to $63.2 billion in 2021, with a CAGR of 12.5%, and is expected to reach $124.3 billion by 2025 and $231.0 billion by 2030[32]. - The demand for new plant protection products is increasing due to traditional varieties' resistance management and product iteration needs[30]. - The company is focusing on developing high-efficiency, low-toxicity, and environmentally friendly products in response to the global trend of reducing chemical pesticide usage[30]. Operational Efficiency and Sustainability - The report indicates a commitment to improving operational efficiency and sustainability practices within the company[12]. - The company has committed to maintaining compliance with safety, health, environment, and quality standards in its operations[12]. - The company has established a comprehensive management system integrating safety, health, environment, and quality (SHEQ&C), enhancing its competitive edge in safety and environmental protection[65]. - The company has implemented a business continuity plan (BCP) to manage risks associated with global economic downturns, ensuring operational resilience[87]. - The company is focusing on enhancing its core competitiveness in environmental protection and production through improved waste management technologies[91]. Governance and Compliance - The company has established a robust governance structure in compliance with relevant laws and regulations, ensuring independent operations and effective internal controls[150]. - The board of directors consists of seven members, including three independent directors, meeting legal requirements and ensuring diverse expertise[151]. - The company has implemented a stock incentive plan to align the interests of management and core employees with those of shareholders, promoting long-term stability and growth[152]. - The company maintains complete independence from its controlling shareholder, with no reliance on any related parties for business operations[153]. - The company has established a comprehensive compliance evaluation system for environmental protection[189]. Environmental Compliance - The company has maintained compliance with all discharge limits, indicating effective pollution control measures[194]. - The company reported a total COD emission of 44.36 tons per year, with a concentration of 319.47 mg/L, which is below the regulatory limit of 500 mg/L[192]. - The company achieved a VOC emission level of 17.86 tons per year, with a concentration of 24.17 mg/m³, which is below the limit of 60 mg/m³[192]. - The company is committed to maintaining compliance with environmental standards and reducing emissions through ongoing monitoring and improvements[192]. - The company has invested significantly in environmental protection measures, aligning with its commitment to sustainable development[200]. Future Outlook and Strategic Initiatives - The company aims for a revenue growth of no less than 10% in its industrial business for 2023 compared to 2022, contingent on macroeconomic conditions[133]. - The company plans to enhance collaboration with key customers and expand market development while ensuring stable supply and operational efficiency[134]. - The company is actively exploring potential mergers and acquisitions to bolster its market position and expand its product offerings[160]. - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 12%[146]. - The company is investing 300 million RMB in R&D for new technologies and product development[146].

Group 1: Event Details - The investor reception day is scheduled for May 18, 2023, from 3:30 PM to 5:30 PM [2] - The event will take place at Huangyan Yaoda Hotel Conference Room, No. 3, Century Avenue, Huangyan District, Taizhou City, Zhejiang Province [2] - Investors must register for the event by contacting the company's securities department between May 11, 2023, 9:00 AM - 11:00 AM and 2:00 PM - 4:00 PM [2] Group 2: Company Representatives - The event will be attended by key company personnel including Chairwoman and CEO Wang Ping, Vice Chairman Peng Yinshi, and other senior executives [2] - Adjustments to the list of attendees may occur due to special circumstances [2] Group 3: Participation Requirements - Individual investors must bring original and photocopies of their personal ID and shareholder card; institutional investors must provide relevant proof documents [2] - The company will verify and archive these documents for regulatory review [2] Group 4: Confidentiality and Efficiency - Investors are required to sign a confidentiality commitment as per Shenzhen Stock Exchange regulations [3] - To enhance reception efficiency, investors are encouraged to submit questions in advance via phone or email [3]